Timothy M Illidge
14PUBLICATIONS
36CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (14)
Sort by Publication Date:
|Feb 27, 2026
A Phase II Study of <sup>177</sup>Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients.Roy H Larsen, Arne Kolstad, Alexander Fosså
|Jan 08, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.Elizabeth H Phillips, Nicholas Counsell, Tim Illidge
|Dec 09, 2023
A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.Chalid Assaf, Timothy M Illidge, Nathalie Waser
|May 27, 2023
Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.Vicky Smith, Dave Lee, Mark Reardon
|Jan 08, 2023
Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.Vicky Smith, Debayan Mukherjee, Anna Maria Tsakiroglou
|Apr 06, 2022
Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.James M Price, Hitesh B Mistry, Guy Betts
Pageof 3
Frequent Collaborators
3 joint publications
Peter J Hoskin
2 joint publications
John Radford
2 joint publications
Elizabeth H Phillips
1 joint publications
S J Whittaker
1 joint publications
J J Scarisbrick
1 joint publications
C E Dearden
1 joint publications
David J Cutter
1 joint publications
Patricia Diez
1 joint publications
Georgios Ntentas
1 joint publications
James M Price
